These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 20182461)
1. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Boultwood J; Perry J; Pellagatti A; Fernandez-Mercado M; Fernandez-Santamaria C; Calasanz MJ; Larrayoz MJ; Garcia-Delgado M; Giagounidis A; Malcovati L; Della Porta MG; Jädersten M; Killick S; Hellström-Lindberg E; Cazzola M; Wainscoat JS Leukemia; 2010 May; 24(5):1062-5. PubMed ID: 20182461 [No Abstract] [Full Text] [Related]
2. [Role of ASXL1 mutation in myeloid malignancies]. Sheng MY; Zhou Y; Xu MJ; Yang FC Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1183-7. PubMed ID: 25130853 [TBL] [Abstract][Full Text] [Related]
3. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Gelsi-Boyer V; Trouplin V; Adélaïde J; Bonansea J; Cervera N; Carbuccia N; Lagarde A; Prebet T; Nezri M; Sainty D; Olschwang S; Xerri L; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D Br J Haematol; 2009 Jun; 145(6):788-800. PubMed ID: 19388938 [TBL] [Abstract][Full Text] [Related]
4. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Damm F; Itzykson R; Kosmider O; Droin N; Renneville A; Chesnais V; Gelsi-Boyer V; de Botton S; Vey N; Preudhomme C; Clavert A; Delabesse E; Park S; Birnbaum D; Fontenay M; Bernard OA; Solary E Leukemia; 2013 Jun; 27(6):1401-3. PubMed ID: 23443343 [No Abstract] [Full Text] [Related]
5. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia. Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005 [TBL] [Abstract][Full Text] [Related]
6. Gene expression signatures of pediatric myelodysplastic syndromes are associated with risk of evolution into acute myeloid leukemia. Bresolin S; Trentin L; Zecca M; Giordan M; Sainati L; Locatelli F; Basso G; te Kronnie G Leukemia; 2012 Jul; 26(7):1717-9. PubMed ID: 22411123 [No Abstract] [Full Text] [Related]
8. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. Gelsi-Boyer V; Brecqueville M; Devillier R; Murati A; Mozziconacci MJ; Birnbaum D J Hematol Oncol; 2012 Mar; 5():12. PubMed ID: 22436456 [TBL] [Abstract][Full Text] [Related]
9. Expression of the interleukin 6 gene in acute myeloid leukemia and myelodysplastic syndromes: a report on 49 cases. Collyn d'Hooghe M; Fenaux P; Lantoine D; Loucheux-Lefebvre M; Kerckaert JP Nouv Rev Fr Hematol (1978); 1990; 32(3):175-7. PubMed ID: 2216700 [TBL] [Abstract][Full Text] [Related]
10. ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Padron E; Yoder S; Kunigal S; Mesa T; Teer JK; Al Ali N; Sekeres MA; Painter JS; Zhang L; Lancet J; Maciejewski JP; Epling-Burnette PK; Sotomayor E; Komrokji RS; List AF Blood; 2014 Jun; 123(23):3675-7. PubMed ID: 24904105 [No Abstract] [Full Text] [Related]
11. AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. Haferlach C; Dicker F; Kohlmann A; Schindela S; Weiss T; Kern W; Schnittger S; Haferlach T Leukemia; 2010 May; 24(5):1065-9. PubMed ID: 20164853 [No Abstract] [Full Text] [Related]
12. Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. Gelsi-Boyer V; Cervera N; Bertucci F; Brecqueville M; Finetti P; Murati A; Arnoulet C; Mozziconacci MJ; Mills KI; Cross NC; Vey N; Birnbaum D Haematologica; 2013 Apr; 98(4):576-83. PubMed ID: 23065512 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631 [TBL] [Abstract][Full Text] [Related]
15. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114 [TBL] [Abstract][Full Text] [Related]
16. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Carbuccia N; Trouplin V; Gelsi-Boyer V; Murati A; Rocquain J; Adélaïde J; Olschwang S; Xerri L; Vey N; Chaffanet M; Birnbaum D; Mozziconacci MJ Leukemia; 2010 Feb; 24(2):469-73. PubMed ID: 19865112 [No Abstract] [Full Text] [Related]
17. Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish. Fang X; Xu S; Zhang Y; Xu J; Huang Z; Liu W; Wang S; Yen K; Zhang W Leukemia; 2021 Aug; 35(8):2299-2310. PubMed ID: 33483612 [TBL] [Abstract][Full Text] [Related]
18. No prognostic impact of the WT1 gene single nucleotide polymorphism rs16754 in pediatric acute myeloid leukemia. Hollink IH; van den Heuvel-Eibrink MM; Zimmermann M; Balgobind BV; Arentsen-Peters ST; Alders M; Willasch A; Kaspers GJ; Trka J; Baruchel A; Creutzig U; Pieters R; Reinhardt D; Zwaan CM J Clin Oncol; 2010 Oct; 28(28):e523-6; author reply e527-e528. PubMed ID: 20644087 [No Abstract] [Full Text] [Related]
19. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis. Lin Y; Zheng Y; Wang ZC; Wang SY Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763 [TBL] [Abstract][Full Text] [Related]